Clinical trials: HCC
Liver Cirrhosis, Hepatocellular Carcinoma
Boramae Hospital Liver Cirrhosis Patient Cohort Study
Liver cirrhosis represents a worldwide health problem and is a major cause of mortality. Cirrhosis is the common end for chronic alcohol abuse and hepatitis C and B virus infections.
- Trial name
- NCT01943318
- Testing
- Liver biopsy, Hepatic venous pressure gradient (HVPG) measurement
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Seoul National University Boramae Hospital
Hepatocellular Carcinoma
PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial
Hepatocellular carcinoma (HCC) is one of the most commonly malignant tumors around the world. Hepatic resection or liver transplantation is the radical method to cure the disease.
- Trial name
- PLATIC (NCT04814043)
- Testing
- PD-1 inhibitor
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Sun Yat-sen University
Liver Malignant Tumors, Cholangiocarcinoma Metastatic
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
Over the past three decades, the treatment of both primary and secondary liver malignancies has been improved by the development and optimization of multiple minimally invasive thermal ablative therapies.
- Conditions
- Liver Malignant Tumors, Cholangiocarcinoma Metastatic, Pancreatic Cancer, Melanoma
- Trial name
- NCT05053555
- Testing
- high dose rate brachytherapy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Hepatocellular
RFA for Small HCC With No-touch Technique and Dual Cooled-Wet Electrode
The purpose of this study is to prospectively compare the clinical outcomes (local tumor progression rate, technical success rate, complication rate) of no touch radiofrequency ablation (RFA) technique for Hepatocellular…
- Trial name
- NCT02806076
- Testing
- No-touch RFA arm, Conventional tumor puncture RFA arm
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Seoul National University Hospital
Carcinoma, Hepatocellular, Biliary Tract Cancer
A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
Phase I study of RO7119929 given orally to participants with unresectable advanced or metastatic primary liver cancers and other solid tumors with predominant liver involvement.
- Conditions
- Carcinoma, Hepatocellular, Biliary Tract Cancer, Secondary Liver Cancer, Liver Metastases
- Trial name
- NCT04338685
- Testing
- RO7119929, Tocilizumab
- Where
- 10 sites in United States, Denmark and 4 more
- Volunteers
- 55 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma
A Pilot Study of Individualized Adaptive Radiation Therapy for Hepatocellular Carcinoma
This is a pilot single arm study with the primary endpoints of feasibility and preliminary estimates of safety and efficacy. This protocol builds on over 25 years of experience with high dose liver RT (Radiation Therapy), and in…
- Trial name
- NCT02460835
- Testing
- Adaptive Radiation Therapy
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- University of Michigan Rogel Cancer Center
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant
This phase I trial studies the side effects and best dose of sorafenib tosylate in treating patients with liver cancer who have undergone a liver transplant.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
- Trial name
- NCT00844168
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Washington
Hepatocellular Carcinoma
Bipolar RFA Using Twin ICW Electrodes vs. Switching Monopolar RFA for Recurrent HCC
This study was conducted to provide preliminary data for the main trial to compare efficacy between bipolar radiofrequency ablation (RFA) using twin internally cooled-wet electrodes and switching monopolar RFA using separable…
- Trial name
- NCT03806218
- Testing
- Bipolar RFA, SM-RFA, Twin internally cooled-wet electrodes
- Where
- South Korea
- Volunteers
- 77 people
- Sponsor
- Seoul National University Hospital
Carcinoma, Hepatocellular
Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol Emulsion
The investigators propose in this trial to test a hepatic chemotherapy, consisting of the hepatic intra-arterial injection Idarubicin, emulsified with Lipiodol, lipid vector, without embolization in the treatment of…
- Trial name
- LIDA-BII (NCT03727633)
- Testing
- Idarubicin and Lipiodol
- Where
- 4 sites in France
- Volunteers
- 44 people
- Sponsor
- University Hospital, Montpellier
Carcinoma, Hepatocellular
Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)
The purpose of this study is to determine the efficacy and safety of pembrolizumab or placebo given with best supportive care (BSC) in Asian participants with previously systemically treated advanced hepatocellular carcinoma…
- Trial name
- NCT03062358
- Testing
- pembrolizumab, best supportive care (BSC)
- Where
- 41 sites in China, Hong Kong and 3 more
- Volunteers
- 453 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatocellular Carcinoma, Hepatitis C Virus Chronic Infection
Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma
CP-675,206 (tremelimumab) is a fully humanized monoclonal antibody that binds to activated T lymphocytes and by enhancing their activation may produce a stimulation of the immune response against tumoral or viral antigens.
- Trial name
- NCT01008358
- Testing
- CP 675,206
- Where
- 3 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Hepatocellular Carcinoma
TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA.
The TheraSphere Post-Approval Study is a post-market, prospective, single-arm, open-label, observational study to support the use of TheraSphere for the treatment of hepatocellular carcinoma (HCC).
- Trial name
- NCT05233098
- Testing
- Technetium-99m macroaggregated albumin (Tc-99m MAA)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Boston Scientific Corporation
Hepatocellular Carcinoma, Cirrhosis
Circulating Cell-free DNA-based Epigenetic Biomarker mSEPT9 for Hepatocellular Carcinoma Detection in Cirrhosis
Brief Summary (Plain-Language Version - Compliant with ClinicalTrials.gov Guidelines) The goal of this observational study is to learn whether a blood test called methylated SEPT9 (mSEPT9) can help diagnose hepatocellular…
- Trial name
- SEPT9_CROSS (NCT03311152)
- Testing
- "Epi proColon 2.0 CE" test from Epigenomics, Inc (Berlin, Germany)
- Where
- France
- Volunteers
- 639 people
- Sponsor
- Central Hospital, Nancy, France
Hepatocellular Carcinoma, Portal Vein Tumor Thrombus
BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases
This single-center, prospective, single-arm Phase II clinical trial is designed to evaluate the efficacy and safety of combining hepatic artery infusion chemotherapy (HAIC, for up to 4 cycles) with iparomlimab/tuvonralimab plus…
- Conditions
- Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Oligometastases, Radiotherapy
- Trial name
- NCT07062055
- Testing
- Anti-VEGF, Immunotherapy, Local Therapy
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Shandong Cancer Hospital and Institute
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
QUILT-3.055 is a Phase 2b, open-label, multicohort study investigating combination immunotherapies in patients with advanced solid tumors who have previously been treated with PD-1/PD-L1 checkpoint inhibitors.
- Conditions
- Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03228667
- Testing
- N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab
- Where
- 35 sites in United States
- Volunteers
- 40 people
- Sponsor
- ImmunityBio, Inc.
Carcinoma, Hepatocellular, Carcinoma, Renal Cell
Regulatory Post Marketing Surveillance Study on Nexavar®
This surveillance are to identify problems/questions regarding adverse events, factors that are considered to affect on safety and efficacy in the clinical practice of using Nexavar
- Trial name
- NCT01012011
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- South Korea
- Volunteers
- 2,845 people
- Sponsor
- Bayer
Hepatocellular Carcinoma
Recurrence and Distant Metastases in Hepatocellular Carcinoma Treated by Transcatheter Arterial Chemoembolization
This project will include at least 40 patients with hepatocellular carcinoma (HCC) who will receive transcatheter arterial chemoembolization (TACE) as a sole method for the management.
- Trial name
- NCT00834028
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Combinational Immunotherapy, Hepatocellular Carcinoma Non-Resectable
Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma
The purpose of this study is to explore the efficacy and safety of hyperbaric oxygen therapy plus Camrelizumab as a second-line treatment in patients with advanced hepatocellular carcinoma who have failed at least 1 previous…
- Conditions
- Combinational Immunotherapy, Hepatocellular Carcinoma Non-Resectable, Hyperbaric Oxygen Therapy
- Trial name
- CCGLC-003 (NCT05031949)
- Testing
- hyperbaric oxygen therapy plus Camrelizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhang Bi Xiang, MD
Intrahepatic Cholangiocarcinoma, Mixed Hepatocellular Cholangiocarcinoma
Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples
The primary objective of this study is to estimate the frequency of FGFR2 fusions in archived intrahepatic cholangiocarcinoma (iCCA) or mixed hepatocellular-cholangiocarcinoma (HCC-CCA) tumor samples
- Conditions
- Intrahepatic Cholangiocarcinoma, Mixed Hepatocellular Cholangiocarcinoma, Cholangiocarcinoma
- Trial name
- NCT02762721
- Where
- 6 sites in United States, Italy
- Volunteers
- 131 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Hepatocellular Carcinoma (HCC)
Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection
Vessels that encapsulate tumor clusters (VETC) are a novel invasive metastatic factor in hepatocellular carcinoma (HCC), operating independently of the epithelial-mesenchyme transition (EMT).
- Trial name
- NCT07077798
- Testing
- Sintilimab, Lenvatinib
- Volunteers
- 234 people
- Sponsor
- Wan-Guang Zhang